EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer

[1]  Jean L Wright,et al.  Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy. , 2013, Clinical breast cancer.

[2]  Hua Li,et al.  EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells , 2013, Journal of experimental & clinical cancer research : CR.

[3]  V. Marquez,et al.  Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. , 2013, Neuro-oncology.

[4]  E. Hurt,et al.  EZH2 Is Required for Breast and Pancreatic Cancer Stem Cell Maintenance and Can Be Used as a Functional Cancer Stem Cell Reporter , 2013, Stem cells translational medicine.

[5]  J. Li,et al.  EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo. , 2012, Oncology letters.

[6]  Massimo Cristofanilli,et al.  Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome , 2011, Cancer.

[7]  W. Woodward,et al.  Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. , 2011, The oncologist.

[8]  N. Park,et al.  Radioprotective effects of Bmi-1 involve epigenetic silencing of oxidase genes and enhanced DNA repair in normal human keratinocytes. , 2011, The Journal of investigative dermatology.

[9]  L. Carey,et al.  Impact of Breast Cancer Molecular Subtypes on Locoregional Recurrence in Patients Treated with Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer , 2011, Annals of Surgical Oncology.

[10]  W. Woodward,et al.  EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. , 2011, Cancer cell.

[11]  W. Woodward,et al.  Overcoming radiation resistance in inflammatory breast cancer , 2010, Cancer.

[12]  E. van Marck,et al.  Is there a role for mammary stem cells in inflammatory breast carcinoma? , 2010, Cancer.

[13]  W. Woodward,et al.  Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. , 2010, International journal of radiation oncology, biology, physics.

[14]  Irving L. Weissman,et al.  Association of reactive oxygen species levels and radioresistance in cancer stem cells , 2009, Nature.

[15]  G. Hannon,et al.  Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells , 2009, Cell.

[16]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[17]  W. Woodward,et al.  The role of locoregional therapy in inflammatory breast cancer. , 2008, Seminars in oncology.

[18]  W. Woodward,et al.  WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells , 2007, Proceedings of the National Academy of Sciences.

[19]  Frank Pajonk,et al.  The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. , 2006, Journal of the National Cancer Institute.

[20]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[21]  Anke Sparmann,et al.  Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.

[22]  S. Merajver,et al.  The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. , 2005, Neoplasia.